Pre-made Emicizumab benchmark antibody ( Bispecific mAb, anti-F9;F10 therapeutic antibody, Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-177

Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-177-1mg 1mg Inquiry
GMP-Bios-ab-177-10mg 10mg Inquiry
GMP-Bios-ab-177-100mg 100mg Inquiry
GMP-Bios-ab-177-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody
INN Name Emicizumab
TargetF9;F10
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG4;G4
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusNFD
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2015
Year Recommended2016
CompaniesChugai Pharmaceutical;Roche
Conditions ApprovedHaemophilia A
Conditions Activena
Conditions Discontinuedna
Development Techna